Logo image of CGC

CANOPY GROWTH CORP (CGC) Stock Fundamental Analysis

NASDAQ:CGC - Nasdaq - CA1380357048 - Common Stock - Currency: USD

1.19  +0.06 (+5.31%)

After market: 1.2 +0.01 (+0.84%)

Fundamental Rating

2

Overall CGC gets a fundamental rating of 2 out of 10. We evaluated CGC against 195 industry peers in the Pharmaceuticals industry. CGC has a bad profitability rating. Also its financial health evaluation is rather negative. CGC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CGC has reported negative net income.
In the past year CGC has reported a negative cash flow from operations.
In the past 5 years CGC always reported negative net income.
CGC had a negative operating cash flow in each of the past 5 years.
CGC Yearly Net Income VS EBIT VS OCF VS FCFCGC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1B -2B -3B

1.2 Ratios

CGC has a Return On Assets of -65.18%. This is in the lower half of the industry: CGC underperforms 66.15% of its industry peers.
Looking at the Return On Equity, with a value of -122.76%, CGC is doing worse than 62.05% of the companies in the same industry.
Industry RankSector Rank
ROA -65.18%
ROE -122.76%
ROIC N/A
ROA(3y)-83.37%
ROA(5y)-56.25%
ROE(3y)-219.63%
ROE(5y)-143.17%
ROIC(3y)N/A
ROIC(5y)N/A
CGC Yearly ROA, ROE, ROICCGC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

With a Gross Margin value of 30.30%, CGC perfoms like the industry average, outperforming 55.90% of the companies in the same industry.
CGC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.3%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CGC Yearly Profit, Operating, Gross MarginsCGC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600 -800

More info and screens

3

2. Health

2.1 Basic Checks

CGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CGC has more shares outstanding
Compared to 5 years ago, CGC has less shares outstanding
CGC has a better debt/assets ratio than last year.
CGC Yearly Shares OutstandingCGC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
CGC Yearly Total Debt VS Total AssetsCGC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of -12.76, we must say that CGC is in the distress zone and has some risk of bankruptcy.
CGC has a Altman-Z score of -12.76. This is in the lower half of the industry: CGC underperforms 75.38% of its industry peers.
CGC has a Debt/Equity ratio of 0.64. This is a neutral value indicating CGC is somewhat dependend on debt financing.
CGC has a Debt to Equity ratio of 0.64. This is in the lower half of the industry: CGC underperforms 65.13% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Altman-Z -12.76
ROIC/WACCN/A
WACC12.13%
CGC Yearly LT Debt VS Equity VS FCFCGC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B 6B

2.3 Liquidity

A Current Ratio of 3.12 indicates that CGC has no problem at all paying its short term obligations.
With a Current ratio value of 3.12, CGC perfoms like the industry average, outperforming 55.38% of the companies in the same industry.
CGC has a Quick Ratio of 2.10. This indicates that CGC is financially healthy and has no problem in meeting its short term obligations.
CGC has a Quick ratio of 2.10. This is comparable to the rest of the industry: CGC outperforms 45.64% of its industry peers.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.1
CGC Yearly Current Assets VS Current LiabilitesCGC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B

More info and screens

3

3. Growth

3.1 Past

CGC shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.55%, which is quite impressive.
Looking at the last year, CGC shows a decrease in Revenue. The Revenue has decreased by -9.49% in the last year.
CGC shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.57% yearly.
EPS 1Y (TTM)36.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.08%
Revenue 1Y (TTM)-9.49%
Revenue growth 3Y-19.22%
Revenue growth 5Y-7.57%
Sales Q2Q%-24.74%

3.2 Future

Based on estimates for the next years, CGC will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.30% on average per year.
CGC is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.64% yearly.
EPS Next Y89.17%
EPS Next 2Y38.4%
EPS Next 3Y23.33%
EPS Next 5Y15.3%
Revenue Next Year7.13%
Revenue Next 2Y6.99%
Revenue Next 3Y5.97%
Revenue Next 5Y4.64%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CGC Yearly Revenue VS EstimatesCGC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M 400M 500M
CGC Yearly EPS VS EstimatesCGC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -20 -40 -60

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CGC. In the last year negative earnings were reported.
Also next year CGC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CGC Price Earnings VS Forward Price EarningsCGC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CGC Per share dataCGC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as CGC's earnings are expected to grow with 23.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.4%
EPS Next 3Y23.33%

More info and screens

0

5. Dividend

5.1 Amount

CGC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CANOPY GROWTH CORP

NASDAQ:CGC (7/2/2025, 8:24:16 PM)

After market: 1.2 +0.01 (+0.84%)

1.19

+0.06 (+5.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-30 2025-05-30/bmo
Earnings (Next)08-07 2025-08-07/bmo
Inst Owners8.19%
Inst Owner Change67.66%
Ins Owners0.94%
Ins Owner Change53.62%
Market Cap250.05M
Analysts46.67
Price Target2.05 (72.27%)
Short Float %9.56%
Short Ratio2.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-136.02%
Min EPS beat(2)-170.88%
Max EPS beat(2)-101.15%
EPS beat(4)0
Avg EPS beat(4)-185.86%
Min EPS beat(4)-240.27%
Max EPS beat(4)-101.15%
EPS beat(8)1
Avg EPS beat(8)-176.05%
EPS beat(12)1
Avg EPS beat(12)-194.61%
EPS beat(16)4
Avg EPS beat(16)-136.89%
Revenue beat(2)1
Avg Revenue beat(2)-3.78%
Min Revenue beat(2)-13.61%
Max Revenue beat(2)6.06%
Revenue beat(4)1
Avg Revenue beat(4)-3.99%
Min Revenue beat(4)-13.61%
Max Revenue beat(4)6.06%
Revenue beat(8)4
Avg Revenue beat(8)2.12%
Revenue beat(12)5
Avg Revenue beat(12)-1.29%
Revenue beat(16)6
Avg Revenue beat(16)-3.44%
PT rev (1m)-21.4%
PT rev (3m)-24.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.47%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.51%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.27
P/FCF N/A
P/OCF N/A
P/B 0.7
P/tB 0.96
EV/EBITDA N/A
EPS(TTM)-4.03
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0.94
BVpS1.7
TBVpS1.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.18%
ROE -122.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.3%
FCFM N/A
ROA(3y)-83.37%
ROA(5y)-56.25%
ROE(3y)-219.63%
ROE(5y)-143.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0.64
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.16%
Cap/Sales 4.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.12
Quick Ratio 2.1
Altman-Z -12.76
F-Score5
WACC12.13%
ROIC/WACCN/A
Cap/Depr(3y)15.39%
Cap/Depr(5y)45.04%
Cap/Sales(3y)2.72%
Cap/Sales(5y)9.89%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.08%
EPS Next Y89.17%
EPS Next 2Y38.4%
EPS Next 3Y23.33%
EPS Next 5Y15.3%
Revenue 1Y (TTM)-9.49%
Revenue growth 3Y-19.22%
Revenue growth 5Y-7.57%
Sales Q2Q%-24.74%
Revenue Next Year7.13%
Revenue Next 2Y6.99%
Revenue Next 3Y5.97%
Revenue Next 5Y4.64%
EBIT growth 1Y48.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.26%
EBIT Next 3Y30.78%
EBIT Next 5Y20.32%
FCF growth 1Y38.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.21%
OCF growth 3YN/A
OCF growth 5YN/A